多形性膠質母細胞瘤治療市場規模、佔有率和成長分析（按治療方法、藥物類別、最終用途和地區分類）—2026-2033年產業預測

預計到 2024 年，多形性膠質母細胞瘤治療市場規模將達到 29.6 億美元，到 2025 年將成長至 32.3 億美元，到 2033 年將成長至 63.8 億美元，在預測期（2026-2033 年）內複合年成長率為 8.9%。

膠質母細胞瘤治療市場預計將迎來顯著成長，這主要得益於膠質母細胞瘤發生率的上升以及研發投入的增加。各大製藥公司強大的產品平臺，加上腦腫瘤發生率的不斷攀升，預計將進一步推動市場擴張。統計數據顯示，腦部癌症的死亡率和診斷率居高不下，凸顯了開發有效治療方法的迫切性。然而，高昂的治療費用和有效藥物研發的困難等挑戰阻礙了治療進展，尤其是在治療資源匱乏的發展中地區。儘管如此，個人化醫療的進步和令人鼓舞的臨床試驗結果，特別是免疫療法、標靶治療和創新治療方法的進展，仍然為市場帶來了巨大的機會。

多形性膠質母細胞瘤治療市場促進因素

全球膠質母細胞瘤治療市場的主要促進因素之一是膠質母細胞瘤（一種高度侵襲性的腦癌）發病率和盛行率的不斷上升。隨著人們對這種惡性腫瘤的認知不斷提高以及診斷技術的進步，越來越多的病例被發現，從而刺激了對有效治療方案的需求。此外，持續的研發活動正在為包括標靶治療和免疫療法在內的新型治療方法鋪平道路。對個人化醫療的日益重視有望改善患者的治療效果，進一步推動市場成長，並促進膠質母細胞瘤治療領域的創新。

限制多形性膠質母細胞瘤治療市場的因素

全球膠質母細胞瘤治療市場的主要限制因素之一是治療方法費用高昂，這限制了低收入地區和醫療體系的患者獲得治療的機會。包括標靶治療和免疫療法在內的創新療法的高成本給患者和醫療服務提供者帶來了沉重的經濟負擔，並可能導致治療效果的差異。此外，膠質母細胞瘤是一種異質性疾病，難以開發出普遍有效的治療方法。而且，某些治療方法缺乏健保覆蓋也會進一步阻礙患者獲得治療，並抑制這一重要腫瘤領域的市場成長和創新。

多形性膠質母細胞瘤治療市場趨勢

在膠質母細胞瘤（GBM）治療領域，個人化醫療已成為一個顯著趨勢，並正在革新治療方法。基於個別基因譜客製化治療方案，能夠提高介入措施的精準性和有效性，並使醫療服務提供者能夠根據腫瘤的特定特徵制定治療方法。基因組監測和生物標記識別技術的進步正在推動這項標靶策略的實施，從而帶來更多個人化的治療選擇，改善患者的預後。這種轉變不僅增強了腫瘤科醫師根據腫瘤生物學獨特性最佳化治療的能力，也推動了對創新診斷工具和治療方法的需求，從而塑造了GBM治療的未來。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析和影響

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 專利分析
• 案例研究

全球多形性膠質母細胞瘤治療市場規模（按治療方法和複合年成長率分類）（2026-2033 年）

• 化療
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • 其他
• 放射治療
  • 體外放射線治療（EBRT）
  • 近距離放射
• 標靶治療
  • 單株抗體
  • 蛋白酪氨酸激酶抑制劑
• 免疫療法
  • 查核點抑制劑
  • 疫苗療法
• 腫瘤電場治療（TTF）
• 外科手術
  • 開顱手術
  • 切片檢查

全球多形性膠質母細胞瘤治療市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院
• 診所
• 門診手術中心
• 研究所

全球多形性膠質母細胞瘤治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ipsen SA
• Sumitomo Dainippon Pharma Co., Ltd.
• Karyopharm Therapeutics Inc.

結論與建議

Glioblastoma Multiforme Treatment Market size was valued at USD 2.96 Billion in 2024 and is poised to grow from USD 3.23 Billion in 2025 to USD 6.38 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).

The glioblastoma multiforme treatment market is poised for substantial growth driven by rising glioblastoma prevalence and a heightened emphasis on research and development. A robust product pipeline from leading pharmaceutical firms, alongside a growing incidence of brain tumors, is expected to further propel market expansion. Statistics indicate significant mortality and diagnosis rates for brain-related cancers, underscoring the urgent need for effective therapies. However, challenges such as high treatment costs and the difficulty in developing efficacious drugs impede progress, particularly in developing regions where access to expensive therapies may be limited. Nevertheless, there are considerable opportunities in the market, particularly in advancing immunotherapies, targeted therapies, and innovative treatment combinations, bolstered by advancements in personalized medicine and promising clinical trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Glioblastoma Multiforme Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Glioblastoma Multiforme Treatment Market Segments Analysis

Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors),immunotherapy(checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics,ambulatory surgical centersand research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Glioblastoma Multiforme Treatment Market

One of the key market drivers for the Global Glioblastoma Multiforme Treatment Market is the rising incidence and prevalence of glioblastoma, a highly aggressive type of brain cancer. As awareness about this malignancy increases and advancements in diagnostic techniques improve, more cases are being detected, leading to higher demand for effective treatment options. Furthermore, ongoing research and development initiatives are paving the way for novel therapies, including targeted treatments and immunotherapies. This growing focus on personalized medicine aims to enhance patient outcomes, further propelling market growth and fostering innovation within the treatment landscape for glioblastoma multiforme.

Restraints in the Glioblastoma Multiforme Treatment Market

One significant market restraint for the global glioblastoma multiforme treatment market is the high cost of therapies and treatments, which can limit accessibility for patients in lower-income regions and healthcare systems. The expensive nature of innovative treatments, including targeted therapies and immunotherapies, poses financial burdens on patients and healthcare providers, potentially leading to disparities in treatment outcomes. Furthermore, the complexity of glioblastoma as a heterogeneous disease makes it challenging to develop universally effective treatments, and the lack of reimbursement for certain therapies may further inhibit patient access, hindering market growth and innovation in this critical area of oncology.

Market Trends of the Glioblastoma Multiforme Treatment Market

The glioblastoma multiforme (GBM) treatment market is witnessing a significant trend towards the adoption of personalized medicine, revolutionizing therapeutic approaches. Tailoring treatments based on individual genetic profiles enhances the precision and efficacy of interventions, enabling healthcare providers to match therapies with specific tumor characteristics. Advances in genomic research and biomarker identification facilitate this targeted strategy, resulting in more specialized treatment options that improve patient outcomes. This shift not only empowers oncologists to optimize therapy based on the biological uniqueness of each patient's tumor but also fosters a growing demand for innovative diagnostic tools and treatments, shaping the future landscape of GBM management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Glioblastoma Multiforme Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • Others
• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy
• Targeted Therapy
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
• Immunotherapy
  • Checkpoint Inhibitors
  • Vaccine Therapy
• Tumor Treating Fields (TTF) Therapy
• Surgery
  • Craniotomy
  • Biopsy

Global Glioblastoma Multiforme Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes

Global Glioblastoma Multiforme Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation